Slaughter and May is advising Hikma Pharmaceuticals PLC in relation to its acquisition of Medlac Pharma Italy, Co. Ltd.
Slaughter and May is advising Hikma Pharmaceuticals PLC (Hikma) in relation to its acquisition of Medlac Pharma Italy, Co. Ltd. (Medlac), an injectable manufacturing company in Vietnam. The acquisition includes a high-quality injectable facility, adjacent vacant land, Medlac’s product portfolio of 23 injectable products, its pipeline and all employees.
The acquisition was announced on 7 November 2018.
Hikma is a leading manufacturer of generic injectables in the US and has a growing presence in Europe and MENA. This acquisition provides Hikma with a foothold in Vietnam, one of the most dynamic emerging markets in Asia. Driven by a growing population, government healthcare reforms and strong economic development, Vietnam has been the fastest growing pharmaceutical market in South East Asia in recent years and this fast-paced growth is expected to continue.
Slaughter and May supported Hikma’s internal legal team and worked closely with Anne Terrasse.